食物纤维的数量和类型与墨西哥性结肠炎 (UC) 患者的活性之间的相关性
Sophia Eugenia Martínez-Vázquez1, José Miguel Corral-Ceballos1, Jesús K Yamamoto-Furusho2
1Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Ciudad de México 14080, Mexico.
患有活性性结肠炎 (UC) 的患者消耗的总和不溶性食纤维较少. 不足够的不可溶性纤维摄入量 (<11g) 是活性UC的危险因素,强调了食纤维对疾病管理的重要性.
科学领域:
- 胃肠病学 胃肠病学
- 营养科学 营养科学
- 临床研究 临床研究
背景情况:
- 食纤维的摄入可能会影响性结肠炎 (UC) 缓解.
- 目前对于UC患者的纤维摄入量建议缺乏.
- 这项研究调查了食纤维和UC疾病活动之间的联系.
研究的目的:
- 评估饮食纤维消费与性结肠炎 (UC) 疾病活动之间的关联.
- 为了确定特定类型的食纤维是否会影响UC活性.
- 为了确定与UC患者纤维摄入相关的潜在风险因素.
主要方法:
- 一项涉及152名确诊性结肠炎 (UC) 患者的横截面研究.
- 用24小时的饮食回忆来评估食纤维摄入量.
- 患者被分为缓解和活跃UC组;统计分析包括斯皮尔曼相关性和后勤回归.
主要成果:
- 有活性UC的患者消耗的总纤维 (p=0.016) 和不溶性纤维 (p=0.018) 显著减少.
- 较低的不溶性纤维摄入量与内镜疾病活性相关 (p=0.038).
- 不溶性纤维与便中calprotectin水平呈反相关性 (r=-0.204,p=0.018);摄入量<11g是临床活性的风险因素 (OR=2.37,p=0.026).
结论:
- 低于推水平的总和不溶性食纤维的消费与活性性结肠炎 (UC) 有关.
- 不溶性纤维的摄入量似乎特别重要,以保持缓解或减少UC的活性.
- 研究结果表明,有针对性的食纤维建议在管理UC方面可能发挥作用.
更多相关视频
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Constipation-Predominant IBS
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
